Osteoarthritis Epidemiology Analysis And Forecast, 2021-2031| MENAFN.COM

Saturday, 20 August 2022 06:26 GMT

Osteoarthritis Epidemiology Analysis And Forecast, 2021-2031


(MENAFN- GlobeNewsWire - Nasdaq)

New York, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report 'Osteoarthritis Epidemiology Analysis and Forecast, 2021-2031' -
OA can occur in more than one region of the body simultaneously and most commonly affects joints in the knee, hip, hand, and spine.
In the 7MM, symptomatic diagnosed prevalent cases of hand OA are expected to increase from 75,194,395 cases in 2021 to 82,739,266 cases in 2031, at an annual growth rate (AGR) of 1.00%. In 2031, the US will have the highest number of symptomatic diagnosed prevalent cases of hand OA in the 7MM, with 36,738,291 cases, whereas the UK will have the fewest symptomatic diagnosed prevalent cases of hand OA with 2,819,264 cases.
In the 7MM, symptomatic diagnosed prevalent cases of knee OA are expected to increase from 20,257,631 cases in 2021 to 22,626,173 cases in 2031, at an AGR of 1.17%. In 2031, the US will have the highest number of diagnosed symptomatic prevalent cases of knee OA in the 7MM, with 10,090,439 cases, whereas France will have the fewest symptomatic diagnosed prevalent cases of knee OA with 728,487 cases.
In the 7MM, symptomatic diagnosed prevalent cases of hip OA are expected to increase from 3,493,407 cases in 2021 to 3,975,929 cases in 2031, at an AGR of 1.38%. In 2031, the US will have the highest number of symptomatic diagnosed prevalent cases of hip OA in the 7MM, with 2,068,615 cases, whereas Germany will have the fewest symptomatic diagnosed prevalent cases of hip OA with 92,268 cases.
Scope
- This report provides an overview of the risk factors, comorbidities, and the global and historical trends for osteoarthritis (OA) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). The report provides a 10-year epidemiological forecast for the total prevalent cases (radiographic), total prevalent cases (symptomatic), and diagnosed prevalent cases (symptomatic) of hand OA, knee OA, and hip OA segmented by age (18 years and older) and sex in these markets.
- The diagnosed prevalent cases (symptomatic) of hand OA, knee OA, and hip OA are further segmented by severity using Kellgren-Lawrence (KL) grading into mild (KL = 2), and moderate to severe (KL = 3 to 4). The model accompanying this report also provides the total prevalent cases (radiographic), total prevalent cases (symptomatic), and diagnosed prevalent cases (symptomatic) of hand OA, knee OA, and hip OA and the listed segments.
- The osteoarthritis epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Reasons to Buy
The osteoarthritis epidemiology series will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global osteoarthritis market.
- Quantify patient populations in the global osteoarthritis market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups that present the best opportunities for osteoarthritis therapeutics in each of the markets covered.
- Enable to understand the magnitude of hand, knee, and hip osteoarthritis and the severity.
Read the full report:
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________




MENAFN05082022004107003653ID1104651782


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.